Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City

Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on tr...

Full description

Bibliographic Details
Main Authors: Bockting, W. (Author), Carballo-Diéguez, A. (Author), D’Aquila, R.T (Author), Footer, K.H.A (Author), Giguere, R. (Author), Greene, G.J (Author), MacCrate, C. (Author), Martinez, M. (Author), Mellman, W. (Author), Rael, C.T (Author), Sherman, S. (Author), Valente, P. (Author)
Format: Article
Language:English
Published: Springer New York LLC 2018
Subjects:
adult
Adult
anti human immunodeficiency virus agent
Anti-HIV Agents
Barriers
emtricitabine plus tenofovir disoproxil
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Facilitators
female
Female
Focus Groups
HIV Infections
HIV prevention
human
Human immunodeficiency virus infection
Humans
information processing
male
Male
New York
New York City
pre-exposure prophylaxis
Pre-Exposure Prophylaxis
PrEP
procedures
psychology
qualitative research
Qualitative Research
social stigma
Social Stigma
transgender
Transgender Persons
Transgender women
Transwomen
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items